Skip to main content
. 2022 Nov 14;41(3):664–674. doi: 10.1200/JCO.22.01000

TABLE 3.

Safety Summary (top) and AEs Suspected to Be Related to Study Treatment (≥ 30% in either group; bottom) in Patients With BRAF V600–Mutant LGGa

graphic file with name jco-41-664-g006.jpg